TY - JOUR
T1 - Hepatotoxicity of contemporary antiretroviral drugs
AU - Rivera, Christina G.
AU - Otto, Ashley O.
AU - Zeuli, John D.
AU - Temesgen, Zelalem
N1 - Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Purpose of reviewTo date, more than 30 antiretroviral drugs have been approved by the Food and Drug Administration for the treatment of HIV infection. As new drugs with better efficacy and safety profile become available for clinical practice, older drugs are either withdrawn from the market or become no longer actively prescribed. We review hepatotoxicity associated with contemporary antiretroviral drugs, with emphasis on data from the past 3 years.Recent findingsAlthough less robust data exists for side effects of contemporary antiretroviral medications recently approved for the management of HIV (i.e., doravirine, ibalizumab, fostemsavir, cabotegravir), the risks of substantial hepatotoxicity appears to be minimal with these agents.SummaryAlthough newer antiretroviral drugs are better tolerated than their earlier counterparts, they are not completely devoid of adverse drug reactions, including hepatotoxicity. Monitoring patients on antiretroviral therapy for treatment-emergent liver injury should continue to be part of routine clinical care.
AB - Purpose of reviewTo date, more than 30 antiretroviral drugs have been approved by the Food and Drug Administration for the treatment of HIV infection. As new drugs with better efficacy and safety profile become available for clinical practice, older drugs are either withdrawn from the market or become no longer actively prescribed. We review hepatotoxicity associated with contemporary antiretroviral drugs, with emphasis on data from the past 3 years.Recent findingsAlthough less robust data exists for side effects of contemporary antiretroviral medications recently approved for the management of HIV (i.e., doravirine, ibalizumab, fostemsavir, cabotegravir), the risks of substantial hepatotoxicity appears to be minimal with these agents.SummaryAlthough newer antiretroviral drugs are better tolerated than their earlier counterparts, they are not completely devoid of adverse drug reactions, including hepatotoxicity. Monitoring patients on antiretroviral therapy for treatment-emergent liver injury should continue to be part of routine clinical care.
KW - HIV infections
KW - anti-HIV agents
KW - antiretroviral agents
KW - chemical and drug-induced liver injury
UR - http://www.scopus.com/inward/record.url?scp=85117740261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117740261&partnerID=8YFLogxK
U2 - 10.1097/COH.0000000000000706
DO - 10.1097/COH.0000000000000706
M3 - Review article
C2 - 34545037
AN - SCOPUS:85117740261
SN - 1746-630X
VL - 16
SP - 279
EP - 285
JO - Current Opinion in HIV and AIDS
JF - Current Opinion in HIV and AIDS
IS - 6
ER -